Christine E. Beattie

The Ohio State University — United States

Medicine · Health Sciences

40h-index5.3kcitations98works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neurogenetic and Muscular Disorders Research(30), RNA modifications and cancer(22), Zebrafish Biomedical Research Applications(22), ATP Synthase and ATPases Research(21), RNA Research and Splicing(18)

Publications98 total

Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
2023Open Access
Supplemental Methods and Figure Legends from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
2023Open Access
Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
2023Open Access
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
2023Open Access
Supplemental Methods and Figure Legends from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
2023Open Access
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
2023Open Access
Data from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
2023Open Access
Data from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
2023Open Access
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
2023Open Access
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
2023Open Access
Figure S3 from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
2023Open Access
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
2023Open Access
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
2023Open Access
Figure S2 from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
2023Open Access
Supplementary Table from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
2023Open Access
Figure S1 from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
2023Open Access
Figure S1 from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
2023Open Access
Supplementary Table from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
2023Open Access
Figure S2 from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
2023Open Access
Supplementary Data from Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
2023· 1 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Le Hao(10), Arthur H.M. Burghes(9), Judith S Eisen(7), Michelle L. McWhorter(6), Alessandra M. Welker(5), Phan Q. Duy(5), David W. Raible(4), Ricardo Pineda(3), Tessa L. Carrel(3), Alison N. Lyon(3), Chunping Wang(3), Paul D. Henion(3), Min An(3), Balveen Kaur(3), Marc A. Wolman(3), James D. Jontes(3), Gary J. Bassell(2), Luciano Saieva(2), Livio Pellizzoni(2), Pamela J. Shaw(2)